UBS Group’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.5M | Sell |
936,055
-411,417
| -31% | -$13.3M | ﹤0.01% | 2067 |
|
|
2026
Q1 | $43.8M | Buy |
1,347,472
+412,547
| +44% | +$13.3M | 0.01% | 1782 |
|
|
2025
Q4 | $32.9M | Sell |
934,925
-407,383
| -30% | -$14.4M | 0.01% | 2071 |
|
|
2025
Q3 | $35.3M | Buy |
1,342,308
+390,781
| +41% | +$11.7M | 0.01% | 1984 |
|
|
2025
Q2 | $25.2M | Buy |
951,527
+354,867
| +59% | +$9.34M | ﹤0.01% | 2135 |
|
|
2025
Q1 | $14.4M | Sell |
596,660
-21,488
| -3% | -$679K | ﹤0.01% | 2663 |
|
|
2024
Q4 | $24.9M | Buy |
618,148
+289,189
| +88% | +$16.5M | ﹤0.01% | 2108 |
|
|
2024
Q3 | $20.8M | Sell |
328,959
-30,423
| -8% | -$1.78M | ﹤0.01% | 1790 |
|
|
2024
Q2 | $19.1M | Buy |
359,382
+85,326
| +31% | +$5.59M | ﹤0.01% | 1722 |
|
|
2024
Q1 | $22.5M | Sell |
274,056
-65,670
| -19% | -$2.92M | 0.01% | 1596 |
|
|
2023
Q4 | $6.32M | Buy |
339,726
+196,015
| +136% | +$2.56M | ﹤0.01% | 2519 |
|
|
2023
Q3 | $1.59M | Sell |
143,711
-13,347
| -8% | -$191K | ﹤0.01% | 3673 |
|
|
2023
Q2 | $2.55M | Sell |
157,058
-30,154
| -16% | -$632K | ﹤0.01% | 3297 |
|
|
2023
Q1 | $3.12M | Buy |
187,212
+141,164
| +307% | +$1.46M | ﹤0.01% | 2960 |
|
|
2022
Q4 | $433K | Buy |
46,048
+4,981
| +12% | +$22.2K | ﹤0.01% | 4832 |
|
|
2022
Q3 | $112K | Sell |
41,067
-1,238
| -3% | -$4.05K | ﹤0.01% | 5617 |
|
|
2022
Q2 | $122K | Sell |
42,305
-34,057
| -45% | -$84.3K | ﹤0.01% | 5276 |
|
|
2022
Q1 | $229K | Sell |
76,362
-255,799
| -77% | -$918K | ﹤0.01% | 5252 |
|
|
2021
Q4 | $1.53M | Buy |
332,161
+61,347
| +23% | +$344K | ﹤0.01% | 3994 |
|
|
2021
Q3 | $1.7M | Buy |
270,814
+102,785
| +61% | +$635K | ﹤0.01% | 3721 |
|
|
2021
Q2 | $1.01M | Sell |
168,029
-137,565
| -45% | -$817K | ﹤0.01% | 4168 |
|
|
2021
Q1 | $1.93M | Buy |
305,594
+220,695
| +260% | +$1.55M | ﹤0.01% | 3595 |
|
|
2020
Q4 | $478K | Sell |
84,899
-251,568
| -75% | -$1.52M | ﹤0.01% | 4637 |
|
|
2020
Q3 | $1.96M | Buy |
336,467
+5,786
| +2% | +$39.8K | ﹤0.01% | 3068 |
|
|
2020
Q2 | $2.38M | Sell |
330,681
-59,926
| -15% | -$398K | ﹤0.01% | 2709 |
|
|
2020
Q1 | $1.83M | Sell |
390,607
-19,227
| -5% | -$118K | ﹤0.01% | 2839 |
|
|
2019
Q4 | $3.29M | Sell |
409,834
-169,656
| -29% | -$1.24M | ﹤0.01% | 3035 |
|
|
2019
Q3 | $3.99M | Buy |
579,490
+15,332
| +3% | +$114K | ﹤0.01% | 2596 |
|
|
2019
Q2 | $4.68M | Buy |
564,158
+291,756
| +107% | +$2.49M | ﹤0.01% | 2378 |
|
|
2019
Q1 | $2.71M | Sell |
272,402
-236,570
| -46% | -$1.98M | ﹤0.01% | 2723 |
|
|
2018
Q4 | $3.89M | Buy |
508,972
+302,815
| +147% | +$3.62M | ﹤0.01% | 2390 |
|
|
2018
Q3 | $3.59M | Buy |
206,157
+123,956
| +151% | +$1.48M | ﹤0.01% | 2663 |
|
|
2018
Q2 | $780K | Buy |
82,201
+18,872
| +30% | +$126K | ﹤0.01% | 3974 |
|
|
2018
Q1 | $277K | Buy |
63,329
+53,329
| +533% | +$295K | ﹤0.01% | 4570 |
|
|
2017
Q4 | $41K | Buy |
+10,000
| New | +$29K | ﹤0.01% | 6011 |
|
|
2017
Q2 | – | Sell |
-4,506
| Closed | -$7K | – | 8010 |
|
|
2017
Q1 | $7K | Buy |
+4,506
| New | +$6.3K | ﹤0.01% | 6832 |
|
|
2016
Q3 | – | Sell |
-3,252
| Closed | -$4K | – | 7960 |
|
|
2016
Q2 | $4K | Buy |
3,252
+767
| +31% | +$1.01K | ﹤0.01% | 7248 |
|
|
2016
Q1 | $4K | Buy |
+2,485
| New | +$5K | ﹤0.01% | 7110 |
|
|
2015
Q4 | – | Sell |
-1,408
| Closed | -$8K | – | 8603 |
|
|
2015
Q3 | $8K | Buy |
+1,408
| New | +$9.04K | ﹤0.01% | 7427 |
|
Other funds holding VKTX
UBS Group's VKTX Position: Q2 2026 in Review
UBS Group reduced its Viking Therapeutics (VKTX) stake by 31% in Q2 2026, selling an estimated $13.3M and leaving 936,055 shares worth $36.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2067.
UBS Group first reported a position in VKTX in Q3 2015 and has held it in 39 quarters since. The position peaked at $43.8M in Q1 2026. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- UBS Group held 936,055 shares of Viking Therapeutics worth $36.5M as of Q2 2026.
- UBS Group sold 411,417 Viking Therapeutics shares in Q2 2026, an estimated $13.3M.
- Viking Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2067 holding.
- UBS Group first reported a position in Viking Therapeutics in Q3 2015 and has held it in 39 quarters since.
- UBS Group's Viking Therapeutics position peaked at $43.8M in Q1 2026.
- 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.